Publications by authors named "Asa Ericsson"

Claim this Profile
E
Estimating the societal cost of type 2 diabetes in Malmö, Sweden: a register-based cost analysis.
Magdalena Annersten Gershater, Alexander Dozet, Åsa Ericsson, Slobodan Zdravkovic

Front Clin Diabetes Healthc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of clinical benefits and economic value of weight loss in a Swedish population using a simulation model.
Marije Galavazi, Ville Wallenius, Volker Schnecke, Åsa Ericsson, Helena Björklund

Obesity (Silver Spring)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Pediatric Obesity Treatment on Long-Term Health.
Resthie R Putri, Pernilla Danielsson, Nils Ekström, Åsa Ericsson, Louise Lindberg

JAMA Pediatr· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The public economic burden of suboptimal type 2 diabetes control upon taxpayers in Sweden: Looking beyond health costs.
Nikolaos Kotsopoulos, Mark P Connolly, Michael Willis, Andreas Nilsson, Åsa Ericsson

Diabetes Obes Metab· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.
Björn Eliasson, Åsa Ericsson, Adam Fridhammar, Andreas Nilsson, Sofie Persson

Pharmacoecon Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data.
Margareta Hellgren, Ann-Marie Svensson, Stefan Franzén, Åsa Ericsson, Soffia Gudbjörnsdottir

Diabetes Obes Metab· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis.
Johan Jendle, Åsa Ericsson, Jens Gundgaard, Jonas Bech Møller, William J Valentine

Diabetes Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden.
Emelie Andersson, Sofie Persson, Nino Hallén, Åsa Ericsson, Desirée Thielke

Diabetologia· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
Johan Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard

J Med Econ· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.
Barnaby Hunt, Brian B Hansen, Åsa Ericsson, Klaus Kallenbach, Sarah N Ali

Adv Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Åsa Ericsson, Adam Fridhammar

J Med Econ· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes.
Åsa Ericsson, Divina Glah, Maria Lorenzi, Jeroen P Jansen, Adam Fridhammar

PLoS One· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden.
Johan Jendle, Åsa Ericsson, Barnaby Hunt, William J Valentine, Richard F Pollock

Diabetes Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.
Lena Landstedt-Hallin, Jens Gundgaard, Åsa Ericsson, Susanne Ellfors-Zetterlund

Curr Med Res Opin· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
Åsa Ericsson, Adam Lundqvist

Appl Health Econ Health Policy· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study.
Martin Ridderstråle, Lyndon Marc Evans, Henrik Holm Jensen, Mette Bøgelund, Marie Markert Jensen, Åsa Ericsson

Health Qual Life Outcomes· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
Lars-Åke Mattsson, Åsa Ericsson, Mette Bøgelund, Ricardo Maamari

Maturitas· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.
William J Valentine, Mark Aagren, Mattias Haglund, Asa Ericsson, Manuela H Gschwend

Scand J Public Health· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort.
Ulf-Göran Gerdtham, L Fredrik Andersson, Asa Ericsson, Sixten Borg, Sven-Arne Jansson

Eur J Health Econ· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the g factor in semiclassical kinetic plasma theory.
Gert Brodin, Mattias Marklund, Jens Zamanian, Asa Ericsson, Piero L Mana

Phys Rev Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost differences for COPD with and without physician-diagnosis.
Sven-Arne Jansson, Anne Lindberg, Asa Ericsson, Sixten Borg, Eva Rönmark

COPD· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.
Claes-Göran Löfdahl, Asa Ericsson, Klas Svensson, Emma Andreasson

Pharmacoeconomics· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease.
Sixten Borg, Asa Ericsson, Jadwiga Wedzicha, Amund Gulsvik, Bo Lundbäck

Value Health· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs of COPD in Sweden according to disease severity.
Sven-Arne Jansson, Fredrik Andersson, Sixten Borg, Asa Ericsson, Elsy Jönsson

Chest· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis